Cefpodoxime proxetil – new opportunities in antibacterial therapy of respiratory infections

The purpose of the expert council was to determine the place of cefpodoxime in the ABT algorithms for upper and lower respiratory tract infections and to form a consensus position on its use in clinical practice. Based on the available data, the possibility of including cefpodoxime in national guidelines for the treatment of rhinosinusitis, acute tonsillopharyngitis, community-acquired pneumonia (CAP), as well as infectious exacerbations of chronic bronchitis (CB) and chronic obstructive pulmonary disease (COPD) is being considered

Status of NSLS-II booster

The National Synchrotron Light Source II is a third generation light source under construction at Brookhaven National Laboratory. The project includes a highly optimized 3 GeV electron storage ring, linac pre-injector and full-energy booster-synchrotron. Budker Institute of Nuclear Physics builds booster for NSLS-II. The booster should accelerate the electron beam continuously and reliably from minimal 170 MeV injection energy to maximal energy of 3.15 GeV and average beam current of 20 mA. The booster shall be capable of multi-bunch and single bunch operation. This paper summarizes the status of NSLS-II booster.Национальный источник синхротронного излучения II является синхротроном третьего поколения, созданным в Брукхевенской национальной лаборатории. Проект включает: высокооптимизированное накопительное кольцо на 3 ГэВ, линейный ускоритель и бустерный синхротрон на полную энергию. Институт ядерной физики им. Г.И. Будкера создает бустер для NSLS-II. Бустер должен надежно и непрерывно ускорять пучок электронов от минимальной энергии инжекции 170 МэВ до максимальной энергии 3,15 ГэВ с током пучка 20 мА. Бустер должен быть способен работать в односгустковом и многосгустковом режимах. Эта статья суммирует состояние дел по бустеру для NSLS-II.Національне джерело синхротронного випромінювання II є синхротроном третього покоління, створеним у Брукхевенській національній лабораторії. Проект включає: високооптимізоване накопичувальне кільце на 3 ГеВ, лінійний прискорювач і бустерний синхротрон на повну енергію. Інститут ядерної фізики ім. Г.І. Будкера створює бустер для NSLS-II. Бустер повинен надійно і безперервно прискорювати пучок електронів від мінімальної енергії інжекції 170 МеВ до максимальної енергії 3,15 ГеВ зі струмом пучка 20 мА. Бустер повинен бути здатний працювати в односгустковому і багатосгустковому режимах. Ця стаття підсумовує стан справ по бустеру для NSLS-II

Sore throat. Crossing problems and finding solutions

E.Yu. Radtsig1, A.V. Gurov1,2 1Pirogov Russian National Research Medical University, Moscow, Russian Federation 2L.I. Sverzhevskiy Research Clinical Institute of Otorhinolaryngology, Moscow, Russian Federation The article presents a brief review of the current issues relating to the treatment of acute infectious inflammatory diseases associated with sore throat. Painful throat is one of the most common reasons for the administration of systemic antibacterial drugs as a baseline therapy which, in turn, may facilitate a rise in antibiotic resistance. Recently the focus has shifted to the antibacterial therapy impact on the qualitative and quantitative composition of the microbiota. The review elucidates the opportunities of successful etiotropic therapy amid a low risk of the antibiotic resistance development and a lack of the adverse effects on the oropharyngeal microbiota. Updated information is provided characterizing the pharmacological activity of a bacterium-produced non-ribosomal antimicrobial peptide Gramicidin S and Cetylpyridinium chloride, an antiseptic agent. The highest potency of topical medications can be achieved due to the combined action of multiple synergis tic components. A potential combined use of Gramicidin S and Cetylpyridinium chloride is discussed in the review from the standpoint of the risk of antibiotic resistance and the impact on microbiota. The authors conclude that for the treatment of infectious inflammatory diseases of the upper respiratory tract associated with sore throat it is advisable to select biocenosis-saving topical etiotropic therapy. Keywords: Gramicidin S, non-ribosomal antimicrobial peptides, Cetylpyridinium chloride, topical etiotropic therapy, bactericidal activity, antibiotic resistance, microbiocenosis-saving therapy, pharyngitis, tonsillopharyngitis. For citation: Radtsig E.Yu., Gurov A.V. Sore throat. Crossing problems and finding solutions. Russian Journal of Woman and Child Health. 2022;5(3):228–236 (in Russ.). DOI: 10.32364/2618-8430-2022-5-3-228-236. <br